Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 20.67
(+743.54%)
Based on the Artiva Biotherapeutics, Inc. Common Stock stock forecast from 4 analysts, the average analyst target price for Artiva Biotherapeutics, Inc. Common Stock is USD 20.67 over the next 12 months. Artiva Biotherapeutics, Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Artiva Biotherapeutics, Inc. Common Stock is Slightly Bullish , which is based on 2 positive signals and 1 negative signals. At the last closing, Artiva Biotherapeutics, Inc. Common Stock’s stock price was USD 2.45. Artiva Biotherapeutics, Inc. Common Stock’s stock price has changed by +9.38% over the past week, -37.34% over the past month and 0% over the last year.
No recent analyst target price found for Artiva Biotherapeutics, Inc. Common Stock
No recent average analyst rating found for Artiva Biotherapeutics, Inc. Common Stock
Company Overview Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California. Read Less
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for p...Read More
Frequently Asked Questions About Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock
Based on ratings from 4 analysts Artiva Biotherapeutics, Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ARTV's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ARTV is USD 20.67 over the next 12 months. The maximum analyst target price is USD 23 while the minimum anlayst target price is USD 18.
Unfortunately we do not have enough data on ARTV's stock to indicate if its overvalued.
The last closing price of ARTV's stock was USD 2.45.
The most recent market capitalization for ARTV is USD 0.10B.
Based on targets from 4 analysts, the average taret price for ARTV is projected at USD 20.67 over the next 12 months.
This means that ARTV's stock price may go up by +743.54% over the next 12 months.
We can't find any ETFs which contains Artiva Biotherapeutics, Inc. Common Stock's stock.
As per our most recent records Artiva Biotherapeutics, Inc. Common Stock has 82 Employees.
Artiva Biotherapeutics, Inc. Common Stock's registered address is 5505 Morehouse Drive, San Diego, CA, United States, 92121.
You can get more information about it from Artiva Biotherapeutics, Inc. Common Stock's website at https://www.artivabio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Frequently Asked Questions About Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock
Based on ratings from 4 analysts Artiva Biotherapeutics, Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ARTV's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ARTV is USD 20.67 over the next 12 months. The maximum analyst target price is USD 23 while the minimum anlayst target price is USD 18.
Unfortunately we do not have enough data on ARTV's stock to indicate if its overvalued.
The last closing price of ARTV's stock was USD 2.45.
The most recent market capitalization for ARTV is USD 0.10B.
Based on targets from 4 analysts, the average taret price for ARTV is projected at USD 20.67 over the next 12 months.
This means that ARTV's stock price may go up by +743.54% over the next 12 months.
We can't find any ETFs which contains Artiva Biotherapeutics, Inc. Common Stock's stock.
As per our most recent records Artiva Biotherapeutics, Inc. Common Stock has 82 Employees.
Artiva Biotherapeutics, Inc. Common Stock's registered address is 5505 Morehouse Drive, San Diego, CA, United States, 92121.
You can get more information about it from Artiva Biotherapeutics, Inc. Common Stock's website at https://www.artivabio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARTV !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
